

Early Stage Launches and Near-term Pipeline Products to Watch¹

PRODUCT	STATUS / DESCRIPTION	CATALYSTS TO WATCH
PHARMA		
Miebo^{®2}	Available in U.S., submitted in Canada 1Q23	U.S. launch in process, Canada approval expected in 2024
SURGICAL		
IOL Portfolio		
IC-8[®] Athera[™]	Available in U.S., select markets in EU, Australia, New Zealand and Singapore	U.S. launch in process
enVista Aspire[™]	Intermediate optimized IOL – available in U.S., submitted in EU; Canada in process	U.S. launch in process, EU & Canada launches expected in 2025
enVista Envvy[™]	Trifocal IOL – approved in Canada, submitted in U.S. and EU	U.S. & Canada launches expected in 2024, EU launch in 2025
enVista Beyond[™]	Extended depth of focus (EDOF) IOL – clinical study ongoing	U.S. launch expected in 2026
Lux Premium IOLs	LuxSmart (EDOF) – available in EU, LuxLife (Trifocal) – submitted in EU	LuxLife (Trifocal) EU launch expected in 2025
Teneo[™]	Excimer laser platform – enrollment for hyperopia study ongoing	Approved for myopia and myopia astigmatism in U.S. in 1Q24
MIMS[®]	Minimally invasive surgical procedure for treatment of glaucoma	EU launch in process
eyeTELLIGENCE[®]	Surgical planning software for EyeTelligence platform	U.S. commercial release in process
seeNOVA	Surgical platform for anterior, posterior and combined procedures	Targeting pilot production of system in 1Q25
VISION CARE		
Contact Lens		
Daily SiHy	Launched SVS in ~50 countries, MF launched in U.S. and Japan	Continuing global roll out, Toric launch expected in 2024
Arise	Ortho-K lens system – registration clinical study ongoing	U.S. PMA supplement approval expected in 2025
Myopia Control	Myopia control contact lens – multi-year study ongoing	Year 1 interim report expected 1H26
Consumer		
Blink[™] NutriTears[®]	Nutritional supplement for dry eyes – launch support activities in-process	U.S. launch expected in 3Q24
Lumify Franchise	Preservative Free – approved in U.S.	Preservative Free U.S. launch expected in 1Q25